Results 11 to 20 of about 643 (132)

Severe Lactic Acidosis Due to Inappropriate Use of Biktarvy in a Patient With AIDS [PDF]

Cureus
Bictegravir-emtricitabine-tenofovir alafenamide is an approved medication for the treatment of acquired immunodeficiency syndrome (AIDS). This medication, also called Biktarvy, includes an integrase strand inhibitor combined with nucleoside reverse transcriptase inhibitors (NRTIs) to prevent viral DNA synthesis and lead to improvements in disease ...
Strike A, Velez Oquendo G, Chowdry S, Kaur G.   +3 more
exaly   +4 more sources

A Rare Case of Resistant Hyperkalemia: Unveiling Biktarvy’s Impact on Renal Function in HIV Management [PDF]

Spartan Medical Research Journal
Malitha Hettiarachchi
exaly   +3 more sources

2348 A Rare Case of Biktarvy-Induced HBV Flare

American Journal of Gastroenterology, 2019
INTRODUCTION: Exacerbation of chronic hepatitis B virus (HBV) is defined as an acute rise in alanine aminotransferase (ALT) more than five times the upper limit of normal. Flare-ups of chronic HBV and human immunodeficiency virus (HIV) coinfection receiving antiretroviral therapy is seldom due to discontinuation or initiation ...
Srilaxmi Gujjula, Mohamed Barakat, Jaideep Misra, Khalil Aloreidi, Leonard Berkowitz, Madhavi Reddy   +5 more
openaire   +3 more sources

Human pharmacokinetics prediction with an in vitro–in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy^® for the treatment of HIV-1 infection

Xenobiotica, 2022
Bictegravir (BIC) is a potent small-molecule integrase strand-transfer inhibitor (INSTI) and a component of Biktarvy®, a single-tablet combination regimen that is currently approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Subramanian, Raju, Wang, Jianhong, Murray, Bernard, Custodio, Joseph, Hao, Jia, Lazerwith, Scott, Staiger, Kelly MacLennan, Mwangi, Judy, Sun, Hailing, Tang, Jennifer, Wang, Kelly, Rhodes, Gerry, Wijaya, Samantha, Zhang, Heather, Smith, Bill J.   +14 more
openaire   +2 more sources

The effect of Biktarvy (B/F/ TAF ) on whole‐body insulin sensitivity, lipid and endocrine profile in healthy volunteers

HIV Medicine
Abstract Background Biktarvy is a single‐tablet anti‐retroviral regimen composed of a second‐generation integrase‐inhibitor (Bictegravir), in combination with tenofovir alafenamide and emtricitabine.
Joseph Heskin, Roya Movahedi, Sujin Kang, Ruth Byrne, Krestine Elecito, Perrine Gridel, Paola Marchesani, Graeme Moyle, Ana Milinkovic, Marta Boffito   +9 more
openaire   +3 more sources

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date [PDF]

HIV/AIDS: Research and Palliative Care, 2018
Lucas Hill,1 Shawn R Smith,1 Maile Young Karris2 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA; 2Department of Medicine, University of California San Diego, San Diego, CA, USA Abstract ...
Hill L, Smith SR, Karris MY
doaj   +2 more sources

Safety and Effectiveness of Biktarvy^® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea. [PDF]

Infect Chemother
We present the results of the 4th year surveillance period of a prospective, multicenter, observational, post-marketing surveillance study that evaluates the safety and effectiveness of Biktarvy in routine clinical practice in Korea. A total of 1,157 patients were included in the safety analysis set. Most patients were male (93.3%) and ART experienced (
Kim SW, Peters J, Lang MG, Lee JA, Cha J, Kim YS.   +5 more
europepmc   +3 more sources

INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial

BMJ Open, 2022
Introduction Cotreatment of HIV and tuberculosis (TB) reduces morbidity and mortality in coinfected patients. Availability of antiretroviral treatment (ART) drug options, including within drug classes, is important, particularly in high HIV/TB burden low
Nesri Padayatchi, Kogieleum Naidoo, Anushka Naidoo, Kelly E Dooley, Nonhlanhla Yende-Zuma, Rubeshan Perumal, Gillian Dorse, Resha Boodhram, Emmanuella Chinonso Osuala   +8 more
doaj   +1 more source

Biktarvy Use in Pregnancy

, 2023
Systematic review on the use of biktarvy during ...
Stephen Lee
core   +1 more source

Clinical efficacy, safety, and subjective experience based on ePRO in HIV‐infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China

Immunity, Inflammation and Disease, Volume 11, Issue 8, August 2023., 2023
This study suggests BIC+FTC+TAF is a safe option for achieving and maintaining virological suppression, both in treatment‐naïve patients with high viral load and treatment‐experienced patients with baseline residual viremia. Since there were almost no drug‐related adverse events with this regimen, and patients' subjective experiences of their own ...
Linghong Kong, Xiaoxin Xie, Yanhua Fu, Lin Gan, Xiaoyan Yang, Shujing Ma, Hai Long   +6 more
wiley   +1 more source